|
21-hydroxylase deficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We determined the ability of CYP2C19 and CYP3A4 to 21-hydroxylate progesterone and 17-hydroxyprogesterone (17OHP), determined the impact of the common P450 oxidoreductase (POR) variant A503V on these activities, and examined correlations between CYP2C19 variants and phenotype in patients with 21OHD.
|
18957504 |
2009 |
|
ACQUIRED IMMUNODEFICIENCY SYNDROME, PROGRESSION TO
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
|
31219150 |
2019 |
|
Acute Chest Syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
CYP3A4*1B allele may be an independent determinant of PRC in patients with ACS, although the variability in response to clopidogrel explained by the six polymorphisms is poor when compared to clinical variables.
|
28179614 |
2017 |
|
Acute Chest Syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to determine the impact of polymorphism of CYP3A subfamily isoenzymes (allelic variants of CYP3A4*22 and CYP3A5*3) on the efficacy clopidogrel in patients with an acute coronary syndrome (ACS), who have undergone percutaneous coronary intervention (PCI).
|
31102151 |
2019 |
|
Acute Chest Syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings suggest that possible autoinduction of drug metabolism by higher total daily doses and induction of cytochrome P450 isoform 3A4 (CYP3A4) by cigarette smoke in liver could be the potential causes of increased total clearance of bisoprolol in patients with ACS.
|
30540686 |
2019 |
|
Acute Chest Syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine the impact of <i>CYP2C19</i> and <i>ABCB1</i> gene polymorphisms and CYP3A4 isoenzyme activity on stent implantation complications among patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI).
|
29075133 |
2017 |
|
Acute Coronary Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to determine the impact of polymorphism of CYP3A subfamily isoenzymes (allelic variants of CYP3A4*22 and CYP3A5*3) on the efficacy clopidogrel in patients with an acute coronary syndrome (ACS), who have undergone percutaneous coronary intervention (PCI).
|
31102151 |
2019 |
|
Acute Coronary Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to determine the impact of <i>CYP2C19</i> and <i>ABCB1</i> gene polymorphisms and CYP3A4 isoenzyme activity on stent implantation complications among patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI).
|
29075133 |
2017 |
|
Acute leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to investigate the association between the genetic polymorphism of cytochrome P450 family 3 subfamily A member 5 (CYP3A5) and the activity of CYP3A and plasma concentrations of daunorubicin (DNR) in patients with acute leukemia.
|
28440407 |
2017 |
|
Acute lymphocytic leukemia
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
|
25305360 |
2016 |
|
Acute lymphocytic leukemia
|
0.070 |
Biomarker
|
disease |
BEFREE |
We evaluated whether SNPs in the cytochrome P450 3A family (CYP3A4*1B, CYP3A5*3 and CYP3A5*6) were associated with relapse risk on a national Children's Cancer Group (CCG) paediatric ALL trial (CCG-1891).
|
12846892 |
2003 |
|
Acute lymphocytic leukemia
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs.
|
15462611 |
2004 |
|
Acute lymphocytic leukemia
|
0.070 |
Biomarker
|
disease |
BEFREE |
The allele frequencies differed significantly among whites, blacks and Hispanics (P < 0.001 for CYP3A5*3, P < 0.001 for CYP3A4*1B and P = 0.004 for NQO1609), thus we performed the comparisons between ALL controls and t-ML patients after accounting for race.
|
12439220 |
2002 |
|
Acute lymphocytic leukemia
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study analyzing the prevalence of the polymorphisms CYP1A1*2A, CYP2E1*5B, CYP3A4*1B, del{GSTT1}, del{GSTM1}, NQO1*2, MTHFR C6777, and TYMS 2R/3R in 443 patients with AL [302 with acute myeloblastic leukemia (AML) and 141 with acute lymphoblastic leukemia (ALL)] and 454 control volunteers, using polymerase chain reaction (PCR)-based methods.
|
17339179 |
2007 |
|
Acute lymphocytic leukemia
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
|
Acute lymphocytic leukemia
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We genotyped eight common single-nucleotide polymorphisms (SNPs) in the CYP3A4 and CYP3A5 genes in 511 children with ALL and investigated whether they influenced the survival of the patients.
|
25266680 |
2015 |
|
Acute monocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.
|
30898762 |
2019 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Sequentially, we looked into the detail of (1) the addiction to cocaine and fentanyl by binding to the dopamine transporter and the μ opioid receptor (DAT and μOR, respectively), (2) the potential drug-drug interaction of cocaine and fentanyl via p-glycoprotein (P-gp) efflux, (3) the metabolism of cocaine and fentanyl in CYP3A4, and (4) the physiologically based pharmacokinetic (PBPK) model for two drugs and their drug-drug interaction at the absorption, distribution, metabolism, and excretion (ADME) level.
|
31257858 |
2019 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
There were positive relationships among AH-R, CYP1A1, CYP2E1 and CYP3A expressions in adenocarcinoma, which suggests a metabolite-mediated cross talk in the gene regulation of these markers.
|
17127240 |
2007 |
|
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells.
|
22363234 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we explored the prognostic value of CYP3A4 and CYP3A5 in lung adenocarcinoma.
|
28381170 |
2017 |
|
Adrenal Cushing's syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP3A4 inhibition reduces the metabolism of exogenous corticosteroids leading to suppression of endogenous steroid production and Cushing's syndrome.
|
28060049 |
2017 |
|
Adult Acute Lymphocytic Leukemia
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Towards this aim we analyzed the CYP3A4-290A/G substitution and three NR3C1 polymorphisms (200G/A, 1220A/G and BclI RFLP) in 222 children with acute lymphoblastic leukemia (ALL) whose treatment protocols, among other components, contained corticosteroid drugs.
|
15462611 |
2004 |
|
Adult Acute Lymphocytic Leukemia
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Sixteen single nucleotide polymorphisms (SNPs) (CYP3A4*1B A>G, CYP3A5*3 G>A, GSTP1 313 A>G, GSTM1 deletion, GSTT1 deletion, MDR1 exon 21 G>T/A, MDR1 exon 26 C>T, MTHFR 677 C>T, MTHFR 1298 A>C, NR3C1 1088 A>G, RFC 80 G>A, TPMT 238 G>C, TPMT 460 G>A, TPMT 719 A>G, VDR intron 8 G>A, VDR FokI T>C) that have been implicated in the pharmacogenetics of ALL therapy were analyzed by TotalPlex amplification and SNP genotyping.
|
18385010 |
2008 |
|
Adult Acute Lymphocytic Leukemia
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study analyzing the prevalence of the polymorphisms CYP1A1*2A, CYP2E1*5B, CYP3A4*1B, del{GSTT1}, del{GSTM1}, NQO1*2, MTHFR C6777, and TYMS 2R/3R in 443 patients with AL [302 with acute myeloblastic leukemia (AML) and 141 with acute lymphoblastic leukemia (ALL)] and 454 control volunteers, using polymerase chain reaction (PCR)-based methods.
|
17339179 |
2007 |